Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
OVIDthis companyOvid Therapeutics Inc.	$3.00	-6.79×	0.92×	16.57×	-7.03×	-129.6%	95.9%	-585.2%	-240.1%	-13.3%	-29.5%	-31.9%	0.1×	-0.02×	0×	10.91×	0.0%	1	10.63	2	C+
ABEOAbeona Therapeutics Inc.	$2.80	3.93×	1.75×	47.95×	2.87×	-76.4%	73.7%	-1536.9%	1223.1%	44.7%	-44.0%	-30.2%	0.16×	-0.68×	-23.92×	6.93×	0.0%	2	-3.55	2	C
LXEOLexeo Therapeutics, Inc. Common Stock	$3.09	-5.34×	2.16×	0×	-4.89×	-69.1%	0.0%	0.0%	0.0%	-40.5%	-42.9%	-18.6%	0.03×	0.56×	-530.37×	11.21×	0.0%	1	5.08	2	B-
MGTXMeiraGTx Holdings plc	$9.40	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
NGNENeurogene Inc.	$26.18	-4.86×	1.65×	0×	-3.92×	-83.6%	0.0%	0.0%	0.0%	-34.1%	-37.5%	-18.0%	0.04×	1.08×	-20,641.6×	16.56×	0.0%	1	6.39	2	C
RAREUltragenyx Pharmaceutical Inc.	$15.69	-3.95×	-28.35×	3.37×	-6.56×	-2636.3%	83.8%	-79.5%	-85.4%	718.8%	-43.5%	-20.8%	-15.95×	-1.78×	-8.63×	2.48×	0.0%	2	-5.22	2	B-
Peer median	—	-4.86×	1.65×	3.37×	-4.89×	-83.6%	73.7%	-79.5%	0.0%	44.7%	-43.5%	-18.6%	0.03×	-0.25×	-23.92×	6.93×	0.0%	2	4.07	2	—